282 related articles for article (PubMed ID: 31073076)
1. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; Kronnie GT; Wiesmüller L; Stilgenbauer S; Selivanova G; Debatin KM; Meyer LH
Haematologica; 2020 Jan; 105(1):170-181. PubMed ID: 31073076
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Ceder S; Eriksson SE; Liang YY; Cheteh EH; Zhang SM; Fujihara KM; Bianchi J; Bykov VJN; Abrahmsen L; Clemons NJ; Nordlund P; Rudd SG; Wiman KG
Cell Death Dis; 2021 Jul; 12(7):709. PubMed ID: 34267184
[TBL] [Abstract][Full Text] [Related]
4. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
Hong Y; Ren T; Wang X; Liu X; Fei Y; Meng S; Han X; Sun C; Shen H; Li L; Qiu L; Qian Z; Zhou S; Zhang H; Wang X
Leukemia; 2022 Sep; 36(9):2269-2280. PubMed ID: 35835991
[TBL] [Abstract][Full Text] [Related]
5. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
6. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.
Chiaretti S; Brugnoletti F; Tavolaro S; Bonina S; Paoloni F; Marinelli M; Patten N; Bonifacio M; Kropp MG; Sica S; Guarini A; Foà R
Haematologica; 2013 May; 98(5):e59-61. PubMed ID: 23403321
[No Abstract] [Full Text] [Related]
8. Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants.
Nagourney AJ; Gipoor JB; Evans SS; D'Amora P; Duesberg MS; Bernard PJ; Francisco F; Nagourney RA
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981018
[No Abstract] [Full Text] [Related]
9. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
10. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis.
Saiki R; Ogawa S
Blood Cancer Discov; 2023 Mar; 4(2):102-105. PubMed ID: 36779909
[TBL] [Abstract][Full Text] [Related]
11. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
12. TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH; Chang WT; Jou ST; Lin TK; Chang YH; Lin CY; Lin KH; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Su YN; Hung CC; Lin DT; Chen HY; Yang YL
Cancer Sci; 2020 Jan; 111(1):229-238. PubMed ID: 31729120
[TBL] [Abstract][Full Text] [Related]
13. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
14. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.
Wang Z; Hu H; Heitink L; Rogers K; You Y; Tan T; Suen CLW; Garnham A; Chen H; Lieschke E; Diepstraten ST; Chang C; Chen T; Moujalled D; Sutherland K; Lessene G; Sieber OM; Visvader J; Kelly GL; Strasser A
Cell Death Differ; 2023 Apr; 30(4):1033-1046. PubMed ID: 36739334
[TBL] [Abstract][Full Text] [Related]
15. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia.
Schittenhelm MM; Walter B; Tsintari V; Federmann B; Bajrami Saipi M; Akmut F; Illing B; Mau-Holzmann U; Fend F; Lopez CD; Kampa-Schittenhelm KM
EBioMedicine; 2019 Apr; 42():340-351. PubMed ID: 30952616
[TBL] [Abstract][Full Text] [Related]
16.
Bordin F; Piovan E; Masiero E; Ambesi-Impiombato A; Minuzzo S; Bertorelle R; Sacchetto V; Pilotto G; Basso G; Zanovello P; Amadori A; Tosello V
Haematologica; 2018 Feb; 103(2):266-277. PubMed ID: 29170254
[TBL] [Abstract][Full Text] [Related]
17. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
[TBL] [Abstract][Full Text] [Related]
18. TP53 in adult acute lymphoblastic leukemia.
Salmoiraghi S; Rambaldi A; Spinelli O
Leuk Lymphoma; 2018 Apr; 59(4):778-789. PubMed ID: 28679301
[TBL] [Abstract][Full Text] [Related]
19. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.
Salmoiraghi S; Montalvo ML; Ubiali G; Tosi M; Peruta B; Zanghi P; Oldani E; Boschini C; Kohlmann A; Bungaro S; Intermesoli T; Terruzzi E; Angelucci E; Cavattoni I; Ciceri F; Bassan R; Rambaldi A; Spinelli O
Haematologica; 2016 Jun; 101(6):e245-8. PubMed ID: 26992948
[No Abstract] [Full Text] [Related]
20. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Li F; Zhu Y; Woods WG; Findley HW
J Pharmacol Exp Ther; 2002 Oct; 303(1):124-31. PubMed ID: 12235242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
